Angiotensin II's antiproliferative effects mediated through AT2-receptors depend on down-regulation of SM-20

Gunter Wolf1, Sigrid Harendza, Regine Schroeder

  • 1Department of Medicine, Division of Nephrology and Osteology, University of Hamburg, Hamburg, Germany. Wolf@uke.uni-hamburg.de

Insights

Angiotensin II (ANG II) inhibits cell proliferation via AT2 receptors by down-regulating the SM-20 gene. This identifies SM-20 as crucial for ANG II

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Endocrinology

Background:

  • Angiotensin II (ANG II) is known to inhibit cell proliferation and induce differentiation through AT2 receptors.
  • The specific genes mediating these ANG II effects, particularly its antimitogenic actions, are not fully understood.
  • PC12 cells, a rat pheochromocytoma cell line, exclusively express AT2 receptors, making them a suitable model for studying ANG II/AT2 receptor interactions.

Purpose of the Study:

  • To identify novel genes involved in the antimitogenic effects of Angiotensin II (ANG II) mediated by AT2 receptors.
  • To characterize the role of the identified SM-20 gene in ANG II-induced growth suppression.
  • To investigate the regulation and cellular localization of SM-20 protein.

Main Methods:

  • Differential display analysis of PC12 cells treated with ANG II to identify differentially expressed genes.
  • Northern blotting to assess SM-20 mRNA expression levels.
  • Western blotting and immunohistochemistry to determine SM-20 protein expression and localization.
  • Functional studies using SM-20 antisense oligonucleotides and inducible overexpression systems.

Main Results:

  • Angiotensin II (ANG II) attenuated PC12 cell proliferation without inducing apoptosis.
  • Differential display identified SM-20 as a gene down-regulated by ANG II in PC12 cells.
  • ANG II suppressed SM-20 mRNA and protein expression in a time-dependent manner, an effect blocked by an AT2 receptor antagonist.
  • SM-20 was localized to the mitochondria, and its expression was also reduced by ANG II in rat glomerular endothelial cells.
  • SM-20 antisense oligonucleotides reduced cell proliferation, while SM-20 overexpression inhibited ANG II's antiproliferative effect.

Conclusions:

  • SM-20 is identified as a key gene mediating the growth-suppressive effects of Angiotensin II (ANG II) through AT2 receptors.
  • SM-20 plays a critical role in regulating cellular processes such as proliferation, differentiation, and apoptosis.
  • These findings highlight SM-20 as a novel target for understanding and potentially modulating ANG II signaling pathways.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...